Home to some of the the world’s best universities and top biotech firms — not to mention a breeding ground for robotics companies — Massachusetts is a hotbed for venture investment. In fact, for the past few years Massachusetts has been neck-and-neck with New York for the number two spot after California, in terms total venture capital funding.
And, according to our most recent Venture Pulse: Global VC report covering 2015, Massachusetts saw $6.3B of investment into VC-backed companies in 2015.
Using CB Insights data we rounded up the biggest Massachusetts deals of 2015 with venture capital involvement (which included a venture firm, corporate venture capital firm, or “super angel” in the round).
- The top Massachusetts deal was DraftKings‘ $300M Series D round, which valued the fantasy sports company at $1.35B (though the company’s recent regulatory troubles have thrown some doubt on its future). Accomplice and GGV Capital have been serial investors in the company. Also investing in the Series D were professional sports leagues including Major League Baseball, Major League Soccer, and the National Hockey League.
- The second largest deal was radiation therapy specialist Mevion Medical Systems‘ $200M Series H, financed by Caxton Health Life Sciences, CHL Medical Partners, Hopu Investment Management, ProQuest Investments, Venrock, and YuanMing Capital.
- In third was SimpliVity‘s $175M Series D round. Accel Partners, CRV, and Kleiner Perkins Caufield & Byers were backers for the enterprise cloud services provider competing with Amazon’s AWS.
See the full list below:
|Rank||Company||Quarter||Amount ($M)||Select Investors|
|1||DraftKings||Q3’15||300||Accomplice, GGV Capital, The Raine Group|
|2||Mevion Medical Systems||Q3’15||200||CHL Medical Partners, Venrock, Caxton Health Life Sciences|
|3||SimpliVity||Q1’15||175||Accel Partners, CRV, Kleiner Perkins Caufield & Byers|
|4||Editas Medicine||Q3’15||120||Google Ventures, Khosla Ventures, Fidelity Investments|
|5||Virgin Pulse||Q2’15||92||Insight Venture Partners, Virgin Group|
|6||Codiak Biosciences||Q4’15||80||Alaska Permanent Fund, Alexandria Real Estate Equities, ARCH Venture Partners, Fidelity Investments, Flagship Ventures|
|6||Onshape||Q3’15||80||New Enterprise Associates, North Bridge Venture Partners, Commonwealth Capital Ventures, Andreessen Horowitz|
|6||Syndax Pharmaceuticals||Q3’15||80||Domain Associates, MPM Capital, Forward Ventures|
|9||Deciphera Pharmaceuticals||Q3’15||75||New Leaf Venture Partners|
|10||Intellia Therapeutics||Q3’15||70||Atlas Venture, Novartis Venture Funds, Fidelity Investments|
|10||Altiostar Networks||Q1’15||70||Cisco Investments|
|12||WAVE Life Sciences||Q3’15||66||RA Capital Management, Kagoshima Shinsangyo Sosei Investment, Fidelity Investments, New Leaf Venture Partners|
|12||Digital Guardian||Q4’15||66||GE Pension Fund, Fairhaven Capital|
|14||Dimension Therapeutics||Q2’15||65||F-Prime Capital, OrbiMed Advisors|
|14||Unum Therapeutics||Q2’15||65||Atlas Venture, F-Prime Capital, Sanofi-Genzyme BioVentures|
|16||Voyager Therapeutics||Q2’15||60||Brookside Capital, Casdin Capital, Partner Fund Management, Wellington Management|
|17||Cybereason||Q4’15||59||CRV, Softbank Corp., Spark Capital|
|18||Ra Pharmaceuticals||Q3’15||58.5||New Enterprise Associates, Morgenthaler Ventures, Novartis Venture Funds|
|19||VionX Energy Corp||Q2’15||58.2||Starwood Energy Group, VantagePoint Capital Partners|
|20||Jounce Therapeutics||Q2’15||56||Foresite Capital Management, Nextech Invest, Redmile Group, Wellington Management|
|21||Neon Therapeutics||Q4’15||55||Access Industries, Clal Biotechnology Industries, Third Rock Ventures|
|21||RaNA Therapeutics||Q3’15||55||Atlas Venture, Monsanto Growth Ventures, Partners Innovation Fund, SR One, Pfizer Venture Investments|
|21||Acquia||Q3’15||55||Centerview Capital, New Enterprise Associates, Split Rock Partners|
|24||Bit9 + Carbon Black||Q4’15||54.5||406 Ventures, Accomplice, Highland Capital Partners, Kleiner Perkins Caufield & Byers|
|25||Allena Pharmaceuticals||Q4’15||53||Frazier Healthcare, HBM BioVentures, Pharmstandard International|
Note: Only equity financings involving a VC were included.
Looking for more venture capital data? Sign up for the CB Insights Venture Capital Database.If you aren’t already a client, sign up for a free trial to learn more about our platform.